Zacks Investment Research upgraded shares of Cellectar Biosciences (NASDAQ:CLRB) from a sell rating to a hold rating in a report released on Friday, June 15th.
According to Zacks, “Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin. “
Separately, ValuEngine upgraded Cellectar Biosciences from a sell rating to a hold rating in a report on Wednesday, May 2nd.
Cellectar Biosciences (NASDAQ:CLRB) last announced its earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). sell-side analysts forecast that Cellectar Biosciences will post -0.73 EPS for the current fiscal year.
An institutional investor recently bought a new position in Cellectar Biosciences stock. Anson Funds Management LP bought a new position in shares of Cellectar Biosciences Inc (NASDAQ:CLRB) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 382,078 shares of the biopharmaceutical company’s stock, valued at approximately $523,000. Cellectar Biosciences comprises 0.4% of Anson Funds Management LP’s holdings, making the stock its 24th largest holding. Anson Funds Management LP owned approximately 2.42% of Cellectar Biosciences as of its most recent filing with the Securities & Exchange Commission. 2.45% of the stock is owned by hedge funds and other institutional investors.
About Cellectar Biosciences
Cellectar Biosciences, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) therapeutic, CLR 131, is in a Phase 1 clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of B-cell malignancies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.